{"nctId":"NCT00443209","briefTitle":"Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)","startDateStruct":{"date":"2007-02-21","type":"ACTUAL"},"conditions":["Migraine"],"count":1068,"armGroups":[{"label":"Telcagepant 280 mg/300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Telcagepant 300 mg soft gel capsules","Drug: Telcagepant 280 mg tablets","Drug: Placebo to rizatriptan tablets"]},{"label":"Rizatriptan 10 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rizatriptan 10 mg tablets","Drug: Placebo to telcagepant capsules","Drug: Placebo to telcagepant tablets"]}],"interventions":[{"name":"Telcagepant 300 mg soft gel capsules","otherNames":[]},{"name":"Telcagepant 280 mg tablets","otherNames":[]},{"name":"Rizatriptan 10 mg tablets","otherNames":[]},{"name":"Placebo to telcagepant capsules","otherNames":[]},{"name":"Placebo to telcagepant tablets","otherNames":[]},{"name":"Placebo to rizatriptan tablets","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 1 year history of migraine (with or without aura)\n* Females of child bearing potential must use acceptable contraception throughout trial\n* In general good health based on screening assessment\n\nExclusion Criteria:\n\n* Pregnant/breast-feeding (or is a female expecting to conceive during study period)\n* History or evidence of stroke/transient ischemic attacks, heart disease, coronary artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled hypertension (high blood pressure), uncontrolled diabetes, or human immunodeficiency virus (HIV) disease\n* Major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)\n* History of gastric, or small intestinal surgery, or has a disease that causes malabsorption\n* History of cancer within the last 5 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With At Least One Triptan-Related Adverse Experience (AE)","description":"Triptan-related AEs are defined as: chest pain, chest tightness, asthenia, paraesthesia, dysaesthesia or hyperaesthesia. Participants were monitored for triptan-related AEs for 14 days after any dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"11.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With At Least One Clinical AE","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination. Participants were monitored for clinical AEs for 14 days after any dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.7","spread":null},{"groupId":"OG001","value":"63.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With At Least One Laboratory AE","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. Participants were monitored for laboratory AEs for 14 days after any dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With At Least One Vital Sign Measurement Outside Predefined Limits of Change","description":"Predefined limits of change were established for vital sign measurements: Systolic Blood Pressure (\\>=180 mm Hg and 20 mm Hg increase OR \\<=90 mm Hg and 20 mm Hg decrease), Diastolic Blood Pressure (\\>=105 mm Hg and 15 mm Hg increase OR \\<=50 mm Hg and 15 mm Hg decrease), Pulse (\\>=120 beats per minute \\[bpm\\] and 15 bpm increase OR \\<=50 bpm and 15 bpm decrease), Body Temperature (\\>38ยบ C \\[oral equivalent\\]) and Respiratory Rate (\\>25 or increase of 10 OR \\<5 or decrease of 10 \\[per minute\\]). Participants were monitored for vital sign measurements outside predefined limits of change for 14 days after any dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participant Migraine Attacks With Pain Freedom (PF) at 2 Hours Post-Dose","description":"Participants were asked to rate their migraine headache severity with ratings of 0=No pain, 1=Mild pain, 2=Moderate pain, and 3=Severe pain. PF at 2 hours post-dose is defined as a decrease from mild, moderate or severe migraine headache (Grade 1, 2, or 3) at baseline to no pain (Grade 0) 2 hours post-dose.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":"29.5"},{"groupId":"OG001","value":"47.5","spread":"29.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":641},"commonTop":["Somnolence","Dry mouth","Dizziness","Nausea","Fatigue"]}}}